Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Crédit Agricole du Morbihan FY26 H1 net profit rises 6.9% to EUR 49.6 million; revenue increases 6% to EUR 152.5 million

Crédit Agricole du Morbihan FY26 H1 net profit rises 6.9% to EUR 49.6 million; revenue increases 6% to EUR 152.5 million

ReutersReuters2026/07/31 15:51
  • Crédit Agricole du Morbihan posted H1 2026 IFRS net income attributable to shareholders up 15.8% to EUR 57.8 million.
  • IFRS net banking income climbed 9.1% to EUR 158.4 million; gross operating income jumped 17.2% to EUR 74.6 million.
  • On a statutory basis, net profit rose 6.9% to EUR 49.6 million; net banking income increased 6.0% to EUR 152.5 million.
  • Total provisions, including the general banking risk fund, reached EUR 357.3 million, or 3.40% of outstanding loans.
  • Customer deposits rose 3.3% to EUR 16.41 billion; outstanding loans increased 2.2% to EUR 10.54 billion, with 8,600 new customers added.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crédit Agricole du Morbihan - Caisse Régionale de Crédit Agricole Mutuel published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607311150OMX_____CNEWS_FR_GNW1001255508_fr) on July 31, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

With support from Ober and Bain Capital, RNA rising star Adarx submits US IPO application

Adarx Pharmaceuticals Inc. has filed for an IPO in the United States to help fund the development of a pipeline of drugs aimed at treating various diseases by regulating gene expression.

智通财经2026/09/05 01:16
With support from Ober and Bain Capital, RNA rising star Adarx submits US IPO application